Applied DNA Sciences, Inc. Total Liabilities
Applied DNA Sciences, Inc. total liabilities. Based on the latest financial reports, Applied DNA Sciences, Inc. (BNBX) has total liabilities worth $1.50 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See BNBX defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Applied DNA Sciences, Inc. (2021–2025)
Total liabilities of Applied DNA Sciences, Inc. from 2021 to 2025. This chart illustrates how Applied DNA Sciences, Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore long-term investment intensity of Applied DNA Sciences, Inc. to see how much of total assets are deployed in long-term investments.
Applied DNA Sciences, Inc. Competitors by Total Liabilities
The table below lists competitors of Applied DNA Sciences, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Inti Kapuas Arowana Tbk
JK:IIKP
|
Indonesia | Rp22.81 Billion |
|
Flexituff Ventures International Limited
NSE:FLEXITUFF
|
India | Rs4.56 Billion |
|
Companhia Tecidos Santanense Ltda
SA:CTSA3
|
Brazil | R$574.03 Million |
|
CT Global Managed Portfolio Trust PLC
LSE:CMPI
|
UK | GBX7.51 Million |
|
Braemar Plc
LSE:BMS
|
UK | GBX69.89 Million |
|
Lyc Healthcare Bhd
KLSE:0075
|
Malaysia | RM216.25 Million |
|
Corero Network Security plc
LSE:CNS
|
UK | GBX13.32 Million |
|
2CUREX AB SEK-10
F:2QE
|
Germany | €4.55 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down Applied DNA Sciences, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Applied DNA Sciences, Inc.'s balance sheet.
Liquidity & Leverage Metrics
Applied DNA Sciences, Inc. Total Liabilities Ratios Explained
Applied DNA Sciences, Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.82 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Applied DNA Sciences, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Applied DNA Sciences, Inc. (2021–2025)
The table below shows the annual total liabilities of Applied DNA Sciences, Inc. from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-09-30 | $2.50 Million | -34.68% |
| 2024-09-30 | $3.82 Million | -56.48% |
| 2023-09-30 | $8.78 Million | -6.17% |
| 2022-09-30 | $9.36 Million | +183.19% |
| 2021-09-30 | $3.30 Million | -- |
About Applied DNA Sciences, Inc.
BNB Plus Corp. provides digital asset treasury services. The company offers real-time data tracking of treasury performance and market indicators. The company, through its subsidiaries, also develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) in the Americas, Europe, Asia, and internationally. The company engages in the enzymatic m… Read more